PMID- 8515721
OWN - NLM
STAT- MEDLINE
DCOM- 19930720
LR  - 20190905
IS  - 0098-1532 (Print)
IS  - 0098-1532 (Linking)
VI  - 21
IP  - 6
DP  - 1993
TI  - Critical observations on neuroblastoma treatment with 
      131-I-metaiodobenzylguanidine at diagnosis.
PG  - 411-5
AB  - Results of treatment with 131-I-Metaiodobenzylguanidine (131-I-MIBG) in patients 
      with resistant neuroblastoma appear encouraging if one considers that most of the 
      patients had far advanced, intensively pre-treated disease. To further explore 
      the potential role of this new drug in untreated patients, we treated 3 children 
      with stage III neuroblastoma. All three of our cases received 131-I-MIBG at 
      relatively low dose with the complete disappearance of the tumor mass in case 1, 
      whereas in cases 2 and 3 CT scan showed a significant reduction of the tumor mass 
      and, interestingly enough, no evidence of 131-I-MIBG uptake of a tracer dose in 
      the remaining tumor. Particularly, in case 2, the persistence and subsequent 
      progression of part of the tumor mass without 131-I-MIBG uptake after a 
      therapeutic dose of 131-I-MIBG, which apparently destroyed the 
      131-I-MIBG-positive cell population, clearly suggest heterogeneity at diagnosis, 
      with a dual neuroblastoma cell population, one with 131-I-MIBG uptake and the 
      other without. Besides the biological implications of the 131-I-MIBG uptake 
      heterogeneity in neuroblastoma at diagnosis, our findings suggest that in stage 
      III neuroblastoma patients even a relatively small dose of 131-I-MIBG 
      administered at diagnosis is sufficient to destroy either the primary tumor 
      completely (case 1) or the part of the tumor (case 2 and 3) which shows 
      131-I-MIBG uptake, without any significant hematologic toxicity. Furthermore, a 
      single course of 131-I-MIBG at the dosage employed does not appear to jeopardize 
      the subsequent use of chemotherapy. In conclusion, if our data are confirmed by 
      further investigation, 131-I-MIBG may be included as a front line drug shortly 
      followed by chemotherapy in future treatment strategies of advanced neuroblastoma 
      without or with minimal bone marrow infiltration.
FAU - Mastrangelo, R
AU  - Mastrangelo R
AD  - Division of Pediatric Oncology, Catholic University of the Sacred Heart, Rome, 
      Italy.
FAU - Lasorella, A
AU  - Lasorella A
FAU - Iavarone, A
AU  - Iavarone A
FAU - Rufini, V
AU  - Rufini V
FAU - Troncone, L
AU  - Troncone L
FAU - Danza, F
AU  - Danza F
FAU - Riccardi, R
AU  - Riccardi R
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Med Pediatr Oncol
JT  - Medical and pediatric oncology
JID - 7506654
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Iodobenzenes)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
SB  - IM
MH  - 3-Iodobenzylguanidine
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Infant
MH  - Iodine Radioisotopes/*therapeutic use
MH  - Iodobenzenes/*therapeutic use
MH  - Male
MH  - Neuroblastoma/diagnosis/*radiotherapy
RF  - 17
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1002/mpo.2950210604 [doi]
PST - ppublish
SO  - Med Pediatr Oncol. 1993;21(6):411-5. doi: 10.1002/mpo.2950210604.